TLDR:
- May Health, a clinical-stage medical device company based in Paris, raised $25M in Series B funding led by Bpifrance and Trill Impact.
- The funding will support the company’s growth and advance its Ovarian Rebalancing™ therapy through the pivotal REBALANCE Study.
May Health, a Paris-based clinical-stage medical device company, has secured $25M in Series B funding. The round was led by Bpifrance and Trill Impact, with participation from founding investor Sofinnova Partners, Avestria Ventures, and Kidron Capital Assets LP. This financing will enable the company to support its growth and advance its Ovarian Rebalancing™ therapy through the pivotal REBALANCE Study, which aims to address PCOS-related infertility.
As part of the funding, Nina Rawal from Trill Impact Ventures Advisory and Jean-Francois Morin from Bpifrance will join May Health’s Board of Directors. CEO Anne Morrissey expressed gratitude to the investors and supporters for their confidence in the company’s team and growth strategy. May Health, under Morrissey’s leadership, is dedicated to developing treatment options for women living with PCOS, with a focus on investigating its Ovarian Rebalancing™ treatment in clinical studies as a safe and straightforward option for activating natural ovulation.
Overall, this funding milestone will help May Health continue its pursuit of becoming a leader in global women’s health and addressing PCOS-related infertility.
